WCLC 2024
Advertisement
Jamie L. Studts, PhD, discusses the use of the QUILS™ system in Kentucky and the importance of community engagement.
Annette McWilliams, MBBS, FRACP, PhD, discusses her IASLC Presidential Symposium presentation on the study.
Robert E. Merritt, MD, MBA, FACS, discusses the analysis he presented at the IASLC 2024 World Conference on Lung Cancer.
The real-world study was presented at the IASLC 2024 World Conference on Lung Cancer.
Dr. Rolfo discusses results of an analysis that evaluated the impact of BMI on TTFields therapy.
Dr. Leighl explains PALOMA-3 data presented at the IASLC 2024 World Conference on Lung Cancer.
The trial is investigating nogapendekin alfa inbakicept-pmln in combination with immune checkpoint inhibitor therapy.
Researchers shared an updated safety analysis from the trial at the IASLC 2024 World Conference on Lung Cancer.
Ken Culver, MD, Director of Research and Clinical Affairs at ALK Positive, discusses the on-going ALK Life Study.
Dr. Halmos weighs in on HARMONi-2, TROPION-Lung 01, the SOHO-01 and Beamion LUNG-1 studies, and more.
Rilertinib showed significantly longer progression-free survival compared with gefitinib.
The studies were highlighted as plenary presentations during a Presidential Symposium at WCLC 2024.
Plinabulin combined with docetaxel showed improved survival in patients with wild-type EGFR NSCLC.
Eric Singhi, MD, and Bruna Pellini, MD, joined Lung Cancers Today at the conference to share their insights on key data.
Narjust Florez, MD, FASCO, discusses meeting highlights, the IASLC 50th Anniversary Celebration, research, and more.
Shirish M. Gadgeel, MD, discusses his presentation on the updated data, with a median follow-up of 31.1 months.
Osimertinib demonstrated a manageable safety profile for the treatment of stage III EGFR-mutated NSCLC.
Caicun Zhou, PhD, MD, presented results during the first Presidential Symposium at the IASLC 2024 WCLC.
More than one-third of patients with platinum-resistant ES-SCLC responded to treatment.
A personalized music therapy regimen also mediated postoperative dyspnea symptoms.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.